Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 2/20 | 0.43 |
| ▸ | TERT | O14746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.34 |
| ▸ | HTR3B | O95264 | 3/20 | 0.34 |
| ▸ | HTR3A | P46098 | 3/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 2/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933214 | 0.91 | APEX1 (0.38) | APEX1TERTMEN1KMT2AHTR2C | |
| SCHEMBL1106631 | 0.87 | APEX1 (0.35) | APEX1TERTHTR2CHTR3EHTR3B | |
| SCHEMBL13493197 | 0.85 | HTR2C (0.36) | APEX1TERTHTR2CHTR2AHTR2B | |
| SCHEMBL13908254 | 0.82 | APEX1 (0.32) | APEX1HTR3A | |
| SCHEMBL1103779 | 0.81 | APEX1 (0.32) | APEX1HTR2C | |
| SCHEMBL15267971 | 0.80 | APEX1 (0.40) | APEX1TERTHTR2CHTR3EHTR3B | |
| SCHEMBL179204 | 0.77 | APEX1 (0.64) | APEX1TERTHTR2CCXCR4 | |
| SCHEMBL13044284 | 0.77 | APEX1 (0.38) | APEX1TERTMEN1KMT2ASIGMAR1 | |
| SCHEMBL27351093 | 0.72 | APEX1 (0.46) | APEX1TERTMEN1KMT2AHTR2C | |
| SCHEMBL13830412 | 0.72 | APEX1 (0.52) | APEX1TERTMEN1KMT2ACXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222239-B2 | quaternary ammonium compounds, conjugated to polymers, used as microbiocides | ALLACCEM, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8188068-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188068-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8153617-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153617-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153618-B2 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153618-B2 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7713955-B2 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | ALLACCEM, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2010019611-A2 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR TOPICAL AND ORAL APPLICATIONS | ALLACCEM, INCORPORATED (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | ALLACCEM, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | ALLACCEM, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | ALLACCEM, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080207581-A1 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | ALLACCEM, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080020127-A1 | Methods and systems for coating a medical device | ALLACCEM, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021212-A1 | Methods and systems for preparing an antimicrobial composition | ALLACCEM, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070202342-A1 | Applying to an oral surface (teeth or gums)one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning; dentistry; bonding agents, resin cements, sealants | ALLACCEM, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069435-A1 | Bridged polycyclic compound based compositions for topical applications for pets | OTC, SLC16A8, SLC16A7 | APEX1 1743/4885TERT 2810/4885MEN1 1095/4885 |
| US-20090054528-A1 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | PAICS, SLC16A8, CAD | APEX1 2744/4885TERT 2645/4885MEN1 1262/4885 |
| US-20100016270-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS | PCSK9, HMGCR, CETP | APEX1 2979/4885TERT 974/4885MEN1 766/4885 |
| US-20080021212-A1 | Methods and systems for preparing an antimicrobial composition | DNMT1, TET2, POLR1C | APEX1 46/4885TERT 229/4885MEN1 2952/4885 |
| US-20080207581-A1 | Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning | DNMT1, TET2, CD14 | APEX1 170/4885TERT 1121/4885MEN1 3302/4885 |
| US-20090074833-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION | BMP2, BMP1, BMP6 | APEX1 3901/4885TERT 919/4885MEN1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.